Related references
Note: Only part of the references are listed.Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)
P. J. Hayden et al.
ANNALS OF ONCOLOGY (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions
Yanping Li et al.
FRONTIERS IN PHARMACOLOGY (2022)
Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
Seema Patel et al.
BLOOD (2022)
CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+Relapsed/Refractory Malignancies
Valentin Ortiz-Maldonado et al.
MOLECULAR THERAPY (2021)
Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy
Jing Pan et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2021)
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Max Jan et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline
Bianca D. Santomasso et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies
Xinyi Xiao et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma
Paolo Strati et al.
BLOOD (2021)
CRISPR/Cas9-Engineered Universal CD19/CD22 Dual-Targeted CAR-T Cell Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Yongxian Hu et al.
CLINICAL CANCER RESEARCH (2021)
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
Nikhil C. Munshi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Direct control of CAR T cells through small molecule-regulated antibodies
Spencer Park et al.
NATURE COMMUNICATIONS (2021)
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy
Lina Zhang et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2021)
Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation
Shuangyou Liu et al.
AMERICAN JOURNAL OF HEMATOLOGY (2021)
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
Tim Sauer et al.
BLOOD (2021)
Therapeutic Potential of TNFα and IL1β Blockade for CRS/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation
Yunshuo Chen et al.
FRONTIERS IN IMMUNOLOGY (2021)
Characterization of HLH-like manifestations as a CRS variant in CD22 CAR T cells
Daniel A. Lichtenstein et al.
BLOOD (2021)
Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Olalekan O. Oluwole et al.
BRITISH JOURNAL OF HAEMATOLOGY (2021)
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
Bijal D. Shah et al.
LANCET (2021)
Ciltacabtagene autoleucel, a B-cell maturation antigendirected chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
Jesus G. Berdeja et al.
LANCET (2021)
CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities
Joseph W. Fischer et al.
FRONTIERS IN IMMUNOLOGY (2021)
Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis
Wen Lei et al.
CANCERS (2021)
Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis
Esraa M. Eloseily et al.
ARTHRITIS & RHEUMATOLOGY (2020)
My jamais vu in post allogeneic hematopoietic cell transplant: a review on secondary hemophagocytosis in adults
Rehab M. Alblooshi et al.
BONE MARROW TRANSPLANTATION (2020)
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha et al.
HAEMATOLOGICA (2020)
Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure
Jordan Gauthier et al.
BLOOD (2020)
THEMIS-SHP1 Recruitment by 4-1BB Tunes LCK-Mediated Priming of Chimeric Antigen Receptor-Redirected T Cells
Chuang Sun et al.
CANCER CELL (2020)
Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia
Noelle Frey et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Management of Immunotherapy-Related Toxicities, Version 1.2020 Featured Updates to the NCCN Guidelines
John A. Thompson et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy
Greta Giordano-Attianese et al.
NATURE BIOTECHNOLOGY (2020)
Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia
Shuangyou Liu et al.
BLOOD CANCER JOURNAL (2020)
Gasdermin E-mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Yuying Liu et al.
SCIENCE IMMUNOLOGY (2020)
Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect
Julien Carvelli et al.
BLOOD (2020)
CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results From a Phase I Anti-CD22 CAR T-Cell Trial
Nirali N. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Granzyme A from cytotoxic lymphocytes cleaves GSDMB to trigger pyroptosis in target cells
Zhiwei Zhou et al.
SCIENCE (2020)
Diagnosis and Management of Secondary HLH/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)
Robert David Sandler et al.
FRONTIERS IN IMMUNOLOGY (2020)
Macrophage, the potential key mediator in CAR-T related CRS
Zhaonian Hao et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2020)
Itacitinib (INCB039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy
Eduardo Huarte et al.
CLINICAL CANCER RESEARCH (2020)
The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis
Sakshi Bami et al.
PEDIATRIC BLOOD & CANCER (2020)
Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients
Kazusa Ishii et al.
JOURNAL OF CLINICAL INVESTIGATION (2020)
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events
Marcela Maus et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
The caspase-3/GSDME signal pathway as a switch between apoptosis and pyroptosis in cancer
Mingxia Jiang et al.
CELL DEATH DISCOVERY (2020)
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Tao Gong et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis
Philipp Wohlfarth et al.
JOURNAL OF INTENSIVE CARE MEDICINE (2019)
Macrophage activation syndrome in adults: recent advances in pathophysiology, diagnosis and treatment
Stuart J. Carter et al.
RHEUMATOLOGY (2019)
Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells
Philipp Karschnia et al.
BLOOD (2019)
Early and late hematologic toxicity following CD19 CAR-T cells
Shalev Fried et al.
BONE MARROW TRANSPLANTATION (2019)
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Eric L. Smith et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT)
Ankit J. Kansagra et al.
BONE MARROW TRANSPLANTATION (2019)
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Jing Pan et al.
LEUKEMIA (2019)
Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome
Chelsea Kotch et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2019)
The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells
Katrin Mestermann et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
Activation of Toll-like Receptor 2 (TLR2) induces Interleukin-6 trans-signaling
Charlotte M. Flynn et al.
SCIENTIFIC REPORTS (2019)
Enhanced CAR T cell expansion and prolonged persistence in pediatric patients with ALL treated with a low-affinity CD19 CAR
Sara Ghorashian et al.
NATURE MEDICINE (2019)
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
Daniel W. Lee et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2019)
GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Rosalie M. Sterner et al.
BLOOD (2019)
Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy
Rebecca A. Gardner et al.
BLOOD (2019)
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial
Frederick L. Locke et al.
LANCET ONCOLOGY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy
Marion Subklewe et al.
TRANSFUSION MEDICINE AND HEMOTHERAPY (2019)
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy
Terry J. Fry et al.
NATURE MEDICINE (2018)
Chimeric antigen receptor T-cell therapy - assessment and management of toxicities
Sattva S. Neelapu et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Chimeric Antigen Receptor T Cell Therapy and the Kidney What the Nephrologist Needs to Know
Kenar D. Jhaveri et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2018)
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Margherita Norelli et al.
NATURE MEDICINE (2018)
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Theodoros Giavridis et al.
NATURE MEDICINE (2018)
Interleukin-6: designing specific therapeutics for a complex cytokine
Christoph Garbers et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Chimeric Antigen Receptor Therapy
Carl H. June et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
S. L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
Robert Q. Le et al.
ONCOLOGIST (2018)
Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia
Bianca D. Santomasso et al.
CANCER DISCOVERY (2018)
Perspectives on Chimeric Antigen Receptor T-Cell immunotherapy for Solid Tumors
Paris Kosti et al.
FRONTIERS IN IMMUNOLOGY (2018)
Activation of the JAK/STAT3 and PI3K/AKT pathways are crucial for IL-6 trans-signaling-mediated pro-inflammatory response in human vascular endothelial cells
Mulugeta M. Zegeye et al.
CELL COMMUNICATION AND SIGNALING (2018)
Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy
Noelle Frey et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2018)
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
Wan-Hong Zhao et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2018)
Driving gene-engineered T cell immunotherapy of cancer
Laura A. Johnson et al.
CELL RESEARCH (2017)
Diagnostic value of serum ferritin and the risk factors and cytokine profiles of hemophagocytic syndrome following allogeneic hematopoietic cell transplantation
Satoru Nanno et al.
LEUKEMIA & LYMPHOMA (2017)
Chemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Yupeng Wang et al.
NATURE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Pyroptosis: Gasdermin-Mediated Programmed Necrotic Cell Death
Jianjin Shi et al.
TRENDS IN BIOCHEMICAL SCIENCES (2017)
Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells
Juliane Gust et al.
CANCER DISCOVERY (2017)
Global Manufacturing of CAR T Cell Therapy
Bruce L. Levine et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2017)
Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy
Kevin A. Hay et al.
BLOOD (2017)
Toxicities of chimeric antigen receptor T cells: recognition and management
Jennifer N. Brudno et al.
BLOOD (2016)
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paulina J. Paszkiewicz et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
CD19 CAR-T cells of defined CD4+: CD8+ composition in adult B cell ALL patients
Cameron J. Turtle et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Jennifer N. Brudno et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Xiuyan Wang et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
Toxicity and management in CAR T-cell therapy
Challice L. Bonifant et al.
MOLECULAR THERAPY-ONCOLYTICS (2016)
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee et al.
LANCET (2015)
A novel immunoregulatory role for NK-cell cytotoxicity in protection from HLH-like immunopathology in mice
Fernando E. Sepulveda et al.
BLOOD (2015)
Current concepts in the diagnosis and management of cytokine release syndrome
Daniel W. Lee et al.
BLOOD (2014)
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Shannon L. Maude et al.
CANCER JOURNAL (2014)
A role for human brain pericytes in neuroinflammation
Deidre Jansson et al.
JOURNAL OF NEUROINFLAMMATION (2014)
IL-6 biology: implications for clinical targeting in rheumatic disease
Leonard H. Calabrese et al.
NATURE REVIEWS RHEUMATOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Marco L. Davila et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
Laurence Fardet et al.
ARTHRITIS & RHEUMATOLOGY (2014)
Unwinding the von Willebrand factor strings puzzle
Karen De Ceunynck et al.
BLOOD (2013)
Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
James N. Kochenderfer et al.
BLOOD (2013)
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
David T. Teachey et al.
BLOOD (2013)
Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens
DeepakBabu Chellapandian et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets
Rafael Lugo-Huitron et al.
OXIDATIVE MEDICINE AND CELLULAR LONGEVITY (2013)
2013 Update of the 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Recommendations for the Medical Therapy of Children With Systemic Juvenile Idiopathic Arthritis and Tuberculosis Screening Among Children Receiving Biologic Medications
Sarah Ringold et al.
ARTHRITIS CARE & RESEARCH (2013)
Biomarkers of endothelial activation/dysfunction in infectious diseases
Andrea V. Page et al.
VIRULENCE (2013)
T Cells Expressing Chimeric Antigen Receptors Can Cause Anaphylaxis in Humans
Marcela V. Maus et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Natural killer cell activation enhances immune pathology and promotes chronic infection by limiting CD8+ T-cell immunity
Philipp A. Lang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Interleukin-6 Modulates Graft-versus-Host Responses after Experimental Allogeneic Bone Marrow Transplantation
Isao Tawara et al.
CLINICAL CANCER RESEARCH (2011)
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
Barbara Savoldo et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Rate of Decline of Ferritin in Patients With Hemophagocytic Lymphohistiocytosis as a Prognostic Variable for Mortality
Tiffany F. Lin et al.
PEDIATRIC BLOOD & CANCER (2011)
Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients
Paivi M. Miettunen et al.
RHEUMATOLOGY (2011)
Sepsis-induced Cardiomyopathy
Francisco J. Romero-Bermejo et al.
CURRENT CARDIOLOGY REVIEWS (2011)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
James N. Kochenderfer et al.
BLOOD (2010)
Sterile inflammation: sensing and reacting to damage
Grace Y. Chen et al.
NATURE REVIEWS IMMUNOLOGY (2010)
CD22 Expression on Blastic Plasmacytoid Dendritic Cell Neoplasms and Reactivity of Anti-CD22 Antibodies to Peripheral Blood Dendritic Cells
Edmunds Z. Reineks et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2009)
T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity
Jennifer D. Stone et al.
IMMUNOLOGY (2009)
Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study
Abderrahman Abdelkefi et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
Graft-versus-leukemia effects of transplantation and donor lymphocytes
Hans-Jochem Kolb
BLOOD (2008)
Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease
Norihiro Nishimoto et al.
BLOOD (2008)
Inflammatory cytokines inhibit ADAMTS13 synthesis in hepatic stellate cells and endothelial cells
W. J. Cao et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2008)
An inducible caspase 9 safety switch for T-cell therapy
KC Straathof et al.
BLOOD (2005)
Benefit of dexamethasone compared with prednisolone for childhood acute lymphoblastic leukaemia: results of the UK Medical Research Council ALL97 randomized trial
CD Mitchell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
T cell activation by antibody-like immunoreceptors: Increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
M Chmielewski et al.
JOURNAL OF IMMUNOLOGY (2004)
Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers under flow
A Bernardo et al.
BLOOD (2004)
Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease
M Serafini et al.
HUMAN GENE THERAPY (2004)
Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation
JI Henter et al.
BLOOD (2002)
Share Paper
